GSKVX000000030825

GSKVX000000030825 is an investigational biological component of a recombinant protein-based immunotherapy developed by GSK for the treatment and prevention of herpes simplex virus (HSV) infections, specifically genital herpes caused by HSV-2. It is currently being evaluated in Phase I/II clinical trials (e.g., trial 2024-510571-37-00) as part of a multi-component vaccine candidate that typically includes recombinant viral glycoproteins and a proprietary adjuvant system such as AS01. The immunotherapy is designed to elicit robust humoral and cellular immune responses to reduce viral shedding and the frequency of clinical recurrences in infected individuals, while also providing potential prophylactic protection in seronegative adults.